Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Integrating genomic features for prognosis in Chinese patients  with B-cell lymphoma following R-CHOP therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYongxian Hu

Discussion

Loading...

Member takes

Overview

This analysis identifies genomic predictors and a novel risk score model for relapse risk in Chinese B-cell lymphoma patients treated with R-CHOP, suggesting improved prognostic accuracy.

Key Points

  • The study aims to identify genomic predictors of treatment response and survival in patients with B-cell lymphoma undergoing R-CHOP therapy.
  • Analyzed tumour and matched oral control DNA samples from 147 Chinese DLBCL patients
  • Utilized targeted sequencing to identify genomic predictors
  • Employed Kaplan–Meier survival analyses and Cox proportional hazards models to assess associations with survival
  • Mutations in TP53, SRP72, MYC, BCL2, and ASXL2 indicate poor progression-free survival (PFS)
  • Developed a risk score that outperformed the International Prognostic Index (IPI) for PFS prediction
  • TP53, SRP72, and MYC mutations were linked to increased relapse risk, leading to a new predictive model

Cite This Study

Yongxian Hu (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4b7https://doi.org/10.1182/blood-2025-3670
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integrating genomic features for prognosis in Chinese patients with diffuse large B-cell lymphoma following R-CHOP therapy2026 · 1 citations
  2. 2Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic Population2024
  3. 3Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results2026
  4. 4Real-world patient-based next-generation sequencing assessments identify a high-risk subgroup and associated gene signature in diffuse large B cell lymphoma2025
  5. 5Concurrent TP53 loss-of-function and epigenetic modifier mutations as a potential predictor of chemoimmunotherapy failure in DLBCL & hgbl2025